000			02155cam a2200265 4500500
005			20250123095926.0
041			_afre
042			_adc
100	1	0	_aAfitska, Kseniia _eauthor
700	1	0	_a Clavel, Julia _eauthor
700	1	0	_a Kisters, Klaus _eauthor
700	1	0	_a Vormann, Jürgen _eauthor
700	1	0	_a Werner, Tanja _eauthor
245	0	0	_aMagnesium citrate supplementation decreased blood pressure and HbA1c in normomagnesemic subjects with metabolic syndrome: a 12-week, placebo-controlled, double-blinded pilot trial
260			_c2021.
500			_a81
520			_aMagnesium (Mg) supplementation was shown to improve metabolic syndrome (MetS) parameters in hypomagnesemic patients. The current study evaluated the role of Mg in normomagnesemic individuals with MetS. Patients were randomly assigned to 400 mg Mg as Mg citrate or placebo daily for 12 weeks. Blood pressure (BP), HbA1c, plasma concentrations of glucose, Mg and Ca, blood-ionized Mg, serum concentrations of cholesterol, triglycerides, vitamin D, creatinine, interleukin-6, and C-reactive protein were measured at baseline and after 12 weeks. Data were obtained from n = 13 in the Mg supplemented and n = 11 in the placebo group. Mg supplementation led to a significant increase in plasma Mg concentration (0.78 ± 0.07 mmol/L to 0.83 ± 0.07 mmol/L) and a decrease in systolic and diastolic BP (baseline: 145 ± 10/85 ± 3 mmHg; 12 weeks: 121 ± 5/79 ± 3 mmHg). HbA1c decreased significantly in the Mg group (6.43 ± 0.64% to 6.15 ± 0.55%), and the difference in change between placebo and Mg group was significant. Serum vitamin D levels significantly increased only in the Mg group. In normomagnesemic individuals with MetS, oral Mg citrate supplementation reduced HbA1c and BP.
690			_ablood pressure
690			_aoral supplementation
690			_amagnesium citrate
690			_aglycemic control
690			_ametabolic syndrome
786	0		_nMagnesium Research | 34 | 3 | 2021-07-01 | p. 130-139 | 0953-1424
856	4	1	_uhttps://shs.cairn.info/revue-magnesium-research-2021-3-page-130?lang=fr&redirect-ssocas=7080
999			_c755420 _d755420